Latest Hemodialysis News
Investigators find that the normalized mean ESA dose decreases as patients' elevation of residence increases.
Researchers linked the condition to warfarin use, diabetes, obesity, recurrent skin trauma, and derangements in mineral metabolism.
In-hospital mortality risk was more than double among patients whose hyperkalemia persisted than those whose potassium levels normalized.
Treatment linked to improved long-term survival, regardless of underlying kidney function.
Findings from a small study suggest that periodontal disease may be a relevant contributing factor.
Iranian study of hemodialysis patients with secondary hyperparathyroidism finds no significant correlation.
Intact parathyroid hormone levels fell significantly in all patients who underwent total Ptx with autotransplant and 91.6% of subtotal Ptx patients.
The non-surgical approach effectively lowered serum parathyroid hormone levels in the short term, but not to the same extent as surgery.
A higher proportion of cinacalcet than placebo recipients met the primary efficacy endpoint of PTH levels of 250 pg/mL or less (25.4% vs. 3.5%).
Trend is independent of intravenous iron use and exposure to erythropoiesis-stimulating agents.
Researchers argue that little evidence exists to support this approach to prevent hyperkalemia.
No new adverse events observed in patients with underlying cardiovascular risk factors who switched to continuous erythropoietin receptor activator.
Researchers suggest conservative care may be suitable option for some patients over 80.
Observed rates of all-cause and cardiovascular mortality and myocardial infarction were consistent with expected rates, study shows.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)